Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

A, Woolloongabba N Clinical Trials

A listing of A, Woolloongabba N clinical trials actively recruiting patients volunteers.


Found (106) clinical trials

The Effect of Acupuncture on Cancer-Related Cognitive Difficulties

This study is being done to explore whether acupuncture can improve cognitive difficulties in survivors of breast, colorectal, and gynecological cancer.


Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease

This trial is an open-label, randomised, multicentric, comparative, Phase II study aiming to evaluate the clinical benefit of a combined treatment associating radiotherapy + Nivolumab + Ipilimumab versus radiotherapy + Capecitabine (standard treatment) in early TNBC patients who have Residual cancer burden (RCB) III residual disease after neoadjuvant chemotherapy. Following ...


Nivolumab Ipilimumab and Short-course Radiotherapy in Adults With Newly Diagnosed MGMT Unmethylated Glioblastoma

This is a single arm, open-label, phase II trial of nivolumab, ipilimumab and short-course radiation therapy in adult patients with newly diagnosed, MGMT unmethylated GBM with the primary objective of determining the overall survival at 1 year.


A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH

Double-blind, randomized, placebo-controlled study to explore the efficacy and safety of elobixibat compared to placebo in adults with NAFLD (nonalcoholic fatty liver disease) or NASH (nonalcoholic steatohepatitis)


Trastuzumab in HER2-positive Biliary Tract Cancer

Trastuzumab is approved for the treatment of HER2-positive breast cancer and gastric cancer. The recent study showed that HER2 overexpression or amplification is noted about 5-15% of total biliary tract cancer patients. The aim of this study is to evaluate the efficacy and safety of trastuzumab in the combination of ...


Growth Hormone Treatment in Children With Phelan McDermid Syndrome

BACKGROUND: Phelan-McDermid syndrome (PMS) is a genetic form of autism spectrum disorder (ASD) associated with developmental delay and hypotonia. IGF-1 promotes brain vessel growth, neurogenesis, and synaptogenesis. The research team previous clinical trial of IGF-1 in patients with Phelan McDermid Syndrome has shown improvement in core ASD symptoms using the ...


A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.

This is a randomized, double-masked, placebo-controlled, parallel-group study. Eligible subjects will be randomized 1:1 to receive either topical lipoic acid choline ester chloride ophthalmic solution 1.5% or placebo, dosed one drop in each eye twice-daily for 3 months.


Alternative Schedule Study For VLA15 a Vaccine Candidate Against Lyme Borreliosis

This is a randomized, observer-blind (subject, Sponsor and investigator/site staff involved in Clinical Evaluation of subjects are blinded), Placebo controlled, multicenter Phase 2 study. A total of 250 healthy subjects,aged 18 to 65 years, will be randomized 2:2:1 to receive either VLA15 with Alum (two different dose levels) or Placebo. ...


Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis in Healthy Adults Aged 18 to 65 Years. Randomized Controlled Observer-blind Phase 2 Study.

This is a randomized, observer-blind, placebo controlled, multicenter Phase 2 study. In the Run-in phase, a total of 120 subjects aged 18 to 40 years will be randomized 1:1:1:1 to receive one of three VLA15 doses (VLA15 low dose, VLA15 medium dose, VLA15 high dose) or Placebo (30 subjects per ...


Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents

Multicenter, placebo-controlled, double-blind, randomized, parallel-group, Phase 2b study in pediatric subjects (aged greater than equal to 6 to less than 18 years of age) with TS. Following a 28-day Screening period and Baseline visit, eligible subjects will be randomized 1:1 to receive either ecopipam hydrochloride (HCl) or matching placebo for ...